- In Focus: Doctors and Lawyers
- Informed Consent: Protecting the Patient Is Protecting Yourself
- The Best Defense Is a Good Offense
- The Five-Step Protocol to Prepare for the Physician Payment Sunshine Act
- New HIPAA Rules: What You Need To Know
- Embezzlement and Fraud: Protect Your Practice
- Body Rejuvenation in Perspective
- Beyond Fat Reduction: RF Therapy for Non-Surgical Skin Tightening
- Editor’s Message
- News & Trends
- Targeting Adult Female Acne
- New in My Practice: Devices
- New in My Practice: Cosmeceuticals
- New Products
- Build Accountability in Your Practice
- Employing Technology for More Personalized Care to Aesthetic Patients
- Master Effective Communication in Aesthetic Business Relationships
- Text Messaging
- Text Messaging
- How to Select the Best Credit Card Vendor
- Juvederm Voluma XC Moves Closer to Market
- Pain Relief for Next April 15th: Four Tax-Saving Ideas You Can Do Now
- 5 Online Marketing Tips for Your Aesthetic Practice
- Checklists Can Improve Patient Safety
- News And Trends
Juvederm Voluma XC Moves Closer to Market
By: Miles Graivier, MD
In Their Words: Allergan’s Juvéderm Voluma™ XC is an injectable hyaluronic acid (HA) dermal filler for cheek augmentation to correct age-related volume deficit in the midface. The filler is a transparent, biodegradable, sterile, crosslinked, hyaluronic acid hydrogel formulated to neutral pH in a physiological buffer.
What it Means: If approved, Juvéderm Voluma XC would be the first HA filler approved for correction of mid-face volume deficit. It’s designed to be a more robust filler with potentially longer longevity than those currently on the US market.
The Data: In the North American clinical trial of Juvéderm Voluma XC (protocol VOLUMA-002), the primary objective was to evaluate the safety and effectiveness of the filler for age-related cheek augmentation in the mid-face. Subjects with moderate to severe age-related mid-face volume deficit were followed for up to 24 months following treatment. Up to 12 ccs of Voluma was allowed to be injected on a patient in the trial. A new 6-point Mid-Face Volume Deficit Scale (MFVDS) was validated and used to quantify the results.
At six months, 86 percent of treated subjects had a 1-point or greater improvement on the MFVDS, the primary endpoint, compared to 39 percent of controls. At Month 24, 67.1 percent of treated subjects had a 1-point or greater improvement in their overall MFVDS since baseline.
What’s Next: The FDA’s General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee voted unanimously in May to recommend approval of Juvéderm Voluma XC. The FDA is expected to follow the panel’s recommendation, and, if it is approved, Allergan anticipates launching Juvéderm Voluma XC in late 2013.
Bottom Line: When Juvéderm Voluma XC gets FDA approval for mid-face volume correction, it will be the first HA gel approved for this usage. The FDA trials showed good soft results with minimal adverse events. The correction appears to last approximately two years (average volume for both malar areas used in study ~6ccs). This will add a good option to our armamentarium for mid-face augmentation.
Zerona Laser Scanning
Despite some buzz around its launch, Zerona Laser Scanner by Erchonia, which uses low-level laser therapy (LLLT) for fat reduction and body slimming, does not appear to be making waves in aesthetic practices. The device aids in the circumferential reduction of the hips, waist, thighs, and upper arms, but aesthetic physicians appear to be more interested in cryolipolysis, ultrasound, and RF technologies.
While improvement in the endocrine function of the adipocyte has been nicely demonstrated in several large level 1 and level 2 studies, the overall results regarding demonstrable, long-lasting circumferential reduction are less impressive than with technologies demonstrating apoptosis. The trend to use the Zerona technology is more toward an assist modality as opposed to a standalone, long-lasting fat reducer.